CITIUS ONCOLOGY, INC.
| Metric | FY2025 | FY2024 | FY2023 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Research and development | $6.4M+30.3% | $4.9M | — | $4.2M | — |
| General and administrative | $8.8M+7.8% | $8.1M+704.4% | $1.0M-82.9% | $5.9M+4182.9% | $138K |
| Stock-based compensation – general and administrative | $8.3M+11.0% | $7.5M | — | $2.0M | — |
| Total Operating Expenses | $23.5M+14.3% | $20.6M | — | $12.1M | — |
| Operating Loss | -$23.5M-14.3% | -$20.6M-1930.7% | -$1.0M | — | -$138K |
| Interest income | $36K | — | — | — | — |
| Interest expense | -$218K | — | — | — | — |
| Total Other Income (Expense), Net | -$182K | — | $3.4M | — | $519K |
| Loss before Income Taxes | -$23.7M-15.2% | -$20.6M | — | -$12.1M | — |
| Income tax expense | $1.1M+83.5% | $576K | — | $576K | — |
| Net Loss | -$24.8M-17.1% | -$21.1M-974.2% | $2.4M+119.1% | -$12.7M-3434.3% | $381K |
| Net Loss Per Share - Basic (in Dollars per share) | -$0.34-9.7% | -$0.31-214.8% | $0.27+242.1% | -$0.19-258.3% | $0.12 |
| Net Loss Per Share – Diluted (in Dollars per share) | -$0.34-9.7% | -$0.31-214.8% | $0.27+242.1% | -$0.19-258.3% | $0.12 |
| Weighted Average Common Shares Outstanding – Basic (in Shares) | 73.3M+7.7% | 68.1M+931.1% | 6.6M-90.2% | 67.5M+4930.7% | 1.3M |
| Weighted Average Common Shares Outstanding – Diluted (in Shares) (in Shares) | 73.3M+7.7% | 68.1M+931.1% | 6.6M-90.2% | 67.5M+4930.7% | 1.3M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
No Form 4 transactions on record.
Informational purposes only, not investment advice.